INCOME TAXES (Notes) |
6 Months Ended |
|---|---|
Jun. 30, 2025 | |
| Income Tax Contingency [Line Items] | |
| Income Tax Disclosure [Text Block] | INCOME TAXES The Company’s effective tax rate was 56% and 10% for the three and six months ended June 30, 2025, respectively, and 29% and 127% for the three and six months ended June 30, 2024, respectively. The following items caused the effective rate to differ from the statutory rate: •Tax expense of $0.1 million and $0.6 million during the three and six months ended June 30, 2025, respectively, and $0.1 million and $1.9 million during the three and six months ended June 30, 2024, respectively, from the tax impacts of share-based compensation awards. •A tax benefit of $0.4 million during the three and six months ended June 30, 2025, respectively, from the completion of a federal tax examination related to research credits. •Tax expense of $1.9 million during the six months ended June 30, 2025, from nondeductible impairment charges. •Tax expense of $0.2 million during the six months ended June 30, 2024, from state taxes related to research and development expenditures. On July 4, 2025, the legislation commonly known as the One Big Beautiful Bill Act (“OBBBA”) was signed into law. Based on the enactment date, the tax impacts of OBBBA are not included in the Company’s financial statements for the six months ended June 30, 2025. The Company is currently evaluating the impacts of the OBBBA provisions on the Company’s financial position, results of operations and cash flows.
|